Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Fda approval save search
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2022-03-16 (Crawled : 22:00) - prnewswire.com
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.72%
H: 0.92%
C: 0.9%
rinvoq treatment fda fda approval approval active ulcerative colitis
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
Published: 2022-03-01 (Crawled : 09:00) - biospace.com/
LEGN | $47.09 -0.06% 360K
|
Health Technology
|
| O: 4.59%
H: 0.0%
C: -7.26%
treatment fda fda approval car-t approval cel therapy
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
PFE A | $25.615 0.89% 9.9M
|
Health Technology
|
| O: 0.09%
H: 0.8%
C: 0.63%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: 0.45%
H: 0.53%
C: 0.42%
treatment fda health fda approval thc approval hiv
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
Published: 2022-01-26 (Crawled : 13:00) - biospace.com/
IMCR | $55.83 1.99% 89K
|
Manufacturing
|
| O: 8.85%
H: 3.44%
C: -1.21%
kimmtrak treatment fda fda approval approval
Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
NVRO | $12.44 0.97% 46K
|
Health Technology
|
| O: -2.27%
H: 1.74%
C: -2.59%
treatment fda fda approval spinal cord approval system
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.56%
H: 0.43%
C: -0.15%
cosentyx novartis treatment fda fda approval approval children
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
Published: 2021-12-20 (Crawled : 18:00) - biospace.com/
ITCI | News 0 d | $72.14 0.19% 440K
|
Health Technology
|
| O: 12.0%
H: 11.72%
C: 3.4%
caplyta treatment fda fda approval approval cel depression therapy
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
VERU | $1.52 7.04% 920K
|
Health Technology
|
| O: 9.28%
H: 0.0%
C: 0.0%
treatment fda fda approval approval
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
Published: 2021-12-07 (Crawled : 23:00) - biospace.com/
DARE | $0.2851 -3.39% 180K
|
Health Technology
|
| O: 1.83%
H: 15.08%
C: 8.54%
treatment fda fda approval bacteria approval
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published: 2021-11-01 (Crawled : 15:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: 0.0%
treatment fda myeloid leukemia leukemia fda approval
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published: 2021-10-29 (Crawled : 20:00) - globenewswire.com
NVS | $93.815 1.35% 410K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
treatment fda myeloid leukemia leukemia fda approval
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published: 2021-10-25 (Crawled : 11:00) - biospace.com/
BHC | $8.655 0.64% 750K
|
Health Technology
|
| O: 0.28%
H: 1.95%
C: 0.9%
CLSD | $1.42 7.58% 100K
|
Health Technology
|
| O: 3.49%
H: 8.51%
C: -0.89%
treatment fda ema fda approval approval macular xipere injection
Adamis Receives FDA Approval for ZIMHINew High-Dose Naloxone Product for the Treatment of Opioid Overdose
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 23.01%
H: 6.47%
C: -11.51%
treatment fda opioid fda approval approval
Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
Published: 2021-10-18 (Crawled : 10:00) - prnewswire.com
OYST | $11.17 0.18% -0.27%
|
Health Technology
|
| O: 9.77%
H: 2.68%
C: -7.29%
dry eye disease nasal spray treatment fda eye fda approval eye disease approval
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Published: 2021-10-15 (Crawled : 12:15) - globenewswire.com
ASND | $142.8 1.36% 55K
|
Health Technology
|
| O: 0.85%
H: 0.48%
C: -0.85%
treatment fda growth hormone growth hormone fda approval
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Published: 2021-10-11 (Crawled : 19:00) - biospace.com/
OCUL | News | $5.07 -13.48% 2.6M
|
Health Technology
|
| O: 0.41%
H: 24.11%
C: 14.91%
new drug treatment fda ocular fda approval drug approval
Janssen Submits Application Seeking U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
Published: 2021-10-08 (Crawled : 12:15) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
treatment fda fda approval approval application
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
Published: 2021-09-29 (Crawled : 18:00) - biospace.com/
MIRM | $23.58 0.04% 55K
|
Health Technology
|
| O: 1.92%
H: 12.51%
C: -2.3%
treatment fda fda approval syndros order
FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
Published: 2021-09-28 (Crawled : 00:00) - prnewswire.com
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.48%
H: 1.6%
C: 0.92%
treatment fda migraine fda approval
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.17%
H: 0.08%
C: -0.47%
INCY | $52.6 -0.42% 380K
|
Health Technology
|
| O: -3.87%
H: 1.0%
C: -4.83%
disease treatment fda fda approval approval
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.